MetaVia Inc.
MetaVia Inc. is a clinical-stage biotechnology company developing novel pharmaceuticals for cardiometabolic diseases. Its current pipeline is focused on two programs targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity, with R&D spending centered on advancing those product candidates through clinical development.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCore pipeline assets under development for MASH and obesity, including Vanoglipel (DA-1241) and DA-1726.
Internal and outsourced R&D activities such as CRO work, consultants, and clinical operations.
Drug product manufacturing, storage, and CMO-related services used for preclinical and clinical studies.
Third-party licensing and shared-services arrangements that support development programs.
Asiakkaat
MetaVia does not sell commercial medicines yet; its primary stakeholders are clinical investigators, CROs, CMOs, and licensing partners that enable drug development. The eventual end customers would be physicians and patients in cardiometabolic disease markets, but near-term value creation depends on advancing the pipeline and securing financing or collaboration support.
CROs, consultants, and trial operators that execute studies and provide development expertise.
CMOs and related suppliers that make and store drug product for preclinical and clinical use.
Third parties such as Dong-A ST that provide shared services, rights, or funding support.
Physicians and patients in MASH and obesity markets who would use approved therapies if development succeeds.
Strategia
MetaVia's near-term strategy is to conserve capital while advancing its MASH and obesity programs through clinical development. Management also expects to supplement cash through equity, debt, or collaboration structures, which makes financing execution as important as scientific progress.
Clinical progress is the main driver of future value and partnering optionality.
The company expects current cash to fund operations only into 2026 and may need more capital to continue trials.
R&D is the primary cash use, so disciplined spending determines how long the pipeline can progress.
Maantiede
MetaVia is a U.S.-based company and reports under U.S. GAAP, with operations centered on development activities rather than a broad commercial footprint. The excerpts provided do not disclose country-level revenue, which is consistent with a clinical-stage business that has not yet built a commercial sales base.
Riskit
MetaVia faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory setbacks, and dependence on external capital. Its going-concern language, limited cash runway, and reliance on equity financing make dilution and trial delays material business risks.
Pipeline value depends on successful outcomes for Vanoglipel and DA-1726.
Kohdistuu: MASH and obesity programs
The company states it expects cash to fund operations only into 2026 and may need additional capital.
Kohdistuu: Clinical trials and corporate operations
Operations have been funded primarily through equity offerings and convertible securities.
Kohdistuu: Existing shareholders
Clinical-stage companies depend on approvals, site execution, and compliance with regulatory requirements.
Kirjanpito
Harkinnanvaraiset erätChanges in warrant valuation flow through earnings and can create non-cash volatility.
Vaikutus: Other income/expense
Employee awards are a recurring non-cash cost and part of R&D overhead.
Vaikutus: Operating expenses and net loss
Management must estimate unpaid clinical, consulting, and manufacturing costs at period end.
Vaikutus: Operating liabilities and expense timing
Clinical development, CMO, CRO, and regulatory costs are expensed as incurred, affecting comparability quarter to quarter.
Vaikutus: Reported operating loss
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Editas Medicine, Inc.
EDIT · Biological Products, (No Diagnostic Substances)
Editas Medicine is a U.S.-based biotechnology company focused on developing gene-editing medicines using CRISPR-based platforms.
VitaNova Life Sciences Corp
VNOV · Wholesale-Apparel, Piece Goods & Notions
VitaNova Life Sciences Corp is a Nevada-incorporated U.S.
vTv Therapeutics Inc.
VTVT · Pharmaceutical Preparations
Viking Therapeutics, Inc.
VKTX · Pharmaceutical Preparations
Viking Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders.
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
Sagimet Biosciences Inc.
SGMT · Pharmaceutical Preparations
Päivitetty: 28.4.2026